DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Inflammatory Conditions – Drug Quantity Management Policy – Per Days
- Rinvoq® (upadacitinib extended-release tablets – AbbVie)

REVIEW DATE: 12/19/2022

OVERVIEW

Rinvoq, a Janus kinase inhibitor (JAKi), is indicated for the following uses:[1]

- **Ankylosing spondylitis**, for treatment of active disease (radiographic or non-radiographic) in adults who have had an inadequate response or intolerance to one or more tumor necrosis factor inhibitors (TNFis).
- **Atopic dermatitis**, for treatment of refractory, moderate to severe atopic dermatitis in patients ≥ 12 years of age, whose disease is not adequately controlled with other systemic drug products (including biologics) or when those therapies are not advisable.
- **Psoriatic arthritis**, for treatment of active disease in adults who have had an inadequate response or intolerance to one or more TNFis.
- **Rheumatoid arthritis**, for treatment of moderately to severely active disease in adults who have had an inadequate response or intolerance to one or more TNFis.
- **Ulcerative colitis**, for treatment of moderately to severely active disease in adults who have had an inadequate response or intolerance to one or more TNFis.

Dosing

Dosage recommendations for Rinvoq are:[1]

- Ankylosing spondylitis: 15 mg QD.
- **Atopic dermatitis**: 15 mg QD.
  - Patients 12 to < 65 years of age who weight ≥ 40 kg: Initiate treatment at 15 mg QD. If an adequate response is not achieved, consider increasing to 30 mg QD.
- **Psoriatic arthritis and rheumatoid arthritis**: 15 mg QD.
- **Ulcerative colitis**: 45 mg QD for 8 weeks, then 15 mg QD.
  - A dose of 30 mg QD may be considered for patients with refractory, severe, or extensive disease.

Availability

Rinvoq is available as 15 mg and 30 mg tablets supplied in bottles containing 30 tablets each.[1] Rinvoq is also available as 45 mg tablets in bottles of 28 tablets.

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Rinvoq. If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity	Home Delivery Maximum Quantity

Rinvoq® (upadacitinib extended-release tablets)	15 mg tablets	30 tablets per 30 days	90 tablets per 90 days
	30 mg tablets	30 tablets per 30 days	90 tablets per 90 days
	45 mg tablets	56 tablets per 365 days	56 tablets per 365 days

CRITERIA

Rinvoq 15 mg and 30 mg tablets
No overrides recommended.

Rinvoq 45 mg tablets

1. If the patient requires additional induction therapy for ulcerative colitis, as verified by the absence of claims for Rinvoq in the past 130 days, approve a one-time override for the requested quantity not to exceed 56 tablets at retail or home delivery.

REFERENCES

1. Rinvoq® tablets [prescribing information]. North Chicago, IL: AbbVie; October 2022.